Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGIV-C Infusion Rates in ITP
NCT00220727Phase 2Completed
- Sponsor
- Grifols
- Start
- Jul 2003
- Primary completion
- Oct 2003
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of intravenous human immunoglobulin in immune thrombocytopenia (ITP), sponsored by Grifols. Started Jul 2003; status: completed.
02
Drugs
intravenous human immunoglobulin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT00220727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00220727.